Targeting multiple kinase pathways in leukemic progenitors and stem cells is essential for improved treatment of Ph+ leukemia in mice. - Wikidata - awgldk - TriplyDB

Targeting multiple kinase pathways in leukemic progenitors and stem cells is essential for improved treatment of Ph+ leukemia in mice.

Targeting multiple kinase pathways in leukemic progenitors and stem cells is essential for improved treatment of Ph+ leukemia in mice.

http://www.wikidata.org/entity/Q35119075

about

The proximal signaling network of the BCR-ABL1 oncogene shows a modular organization Profile of bosutinib and its clinical potential in the treatment of chronic myeloid leukemia Chemotherapeutic agents circumvent emergence of dasatinib-resistant BCR-ABL kinase mutations in a precise mouse model of Philadelphia chromosome-positive acute lymphoblastic leukemia Ph+/VE-cadherin+ identifies a stem cell like population of acute lymphoblastic leukemia sustained by bone marrow niche cells Stem Cell Hierarchy and Clonal Evolution in Acute Lymphoblastic Leukemia Molecular mechanisms for survival regulation of chronic myeloid leukemia stem cells Kinase-independent mechanisms of resistance of leukemia stem cells to tyrosine kinase inhibitors Current concepts in pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia Resistance to tyrosine kinase inhibition therapy for chronic myelogenous leukemia: a clinical perspective and emerging treatment options Conformational Control Inhibition of the BCR-ABL1 Tyrosine Kinase, Including the Gatekeeper T315I Mutant, by the Switch-Control Inhibitor DCC-2036 Secondary mutations as mediators of resistance to targeted therapy in leukemia Src activation plays an important key role in lymphomagenesis induced by FGFR1 fusion kinases Survival regulation of leukemia stem cells Hypoxia-inducing factors as master regulators of stemness properties and altered metabolism of cancer- and metastasis-initiating cells LSK derived LSK- cells have a high apoptotic rate related to survival regulation of hematopoietic and leukemic stem cells ATRA-induced cellular differentiation and CD38 expression inhibits acquisition of BCR-ABL mutations for CML acquired resistance The Chromatin Regulator CHD8 Is a Context-Dependent Mediator of Cell Survival in Murine Hematopoietic Malignancies Mapping of apoptin-interaction with BCR-ABL1, and development of apoptin-based targeted therapy.The antibiotic potential of prokaryotic IMP dehydrogenase inhibitors Transient inhibition of ATM kinase is sufficient to enhance cellular sensitivity to ionizing radiation Dasatinib in the treatment of chronic myeloid leukemia in accelerated phase after imatinib failure: the START a trial.Bosutinib as a fourth-line therapy for a patient with T315I-positive lymphoid blastic phase chronic myeloid leukemia: A case report.Effective and selective targeting of leukemia cells using a TORC1/2 kinase inhibitor PTEN is a tumor suppressor in CML stem cells and BCR-ABL-induced leukemias in mice Global phosphoproteomics reveals crosstalk between Bcr-Abl and negative feedback mechanisms controlling Src signaling.Molecular characterization of c-Abl/c-Src kinase inhibitors targeted against murine tumour progenitor cells that express stem cell markers.The SCLtTAxBCR-ABL transgenic mouse model closely reflects the differential effects of dasatinib on normal and malignant hematopoiesis in chronic phase-CML patients BCR-ABL enhances differentiation of long-term repopulating hematopoietic stem cells Loss of the Alox5 gene impairs leukemia stem cells and prevents chronic myeloid leukemia.Bcl2 is not required for the development and maintenance of leukemia stem cells in mice.Association between imatinib-resistant BCR-ABL mutation-negative leukemia and persistent activation of LYN kinase.Functional ramifications for the loss of P-selectin expression on hematopoietic and leukemic stem cells.Natural killer cell mediated missing-self recognition can protect mice from primary chronic myeloid leukemia in vivo.Arachidonate 15-lipoxygenase is required for chronic myeloid leukemia stem cell survival.Hedgehog signalling is essential for maintenance of cancer stem cells in myeloid leukaemia.CD44 targets Wnt/β-catenin pathway to mediate the proliferation of K562 cells Tyrosine kinase inhibition: a therapeutic target for the management of chronic-phase chronic myeloid leukemia.Dasatinib inhibits the growth of molecularly heterogeneous myeloid leukemias.Activation of the Hedgehog pathway in chronic myelogeneous leukemia patients.Δ12-prostaglandin J3, an omega-3 fatty acid-derived metabolite, selectively ablates leukemia stem cells in mice

P2860

Q24294830-7B1CE7DF-15CD-4A81-A06E-687D8FE86883 Q24607114-6226F322-BF5C-4F39-BA79-D53E8A29362F Q24622397-54E610C7-B704-414C-9C37-1FC1C2F103D7 Q24650730-C0F842DB-B6C9-489C-8E71-03A40298BD3F Q26799954-2E48C979-291C-41D9-B43C-559552D7DEE3 Q26828528-84F77F2E-8A49-4165-9FF7-4D439467E539 Q26849792-33E09AE3-F290-4690-B077-20B0EF269486 Q27025242-661FA9A3-6A29-47A8-BA48-BAD57C1DE798 Q27028181-B47D25F1-8075-4E62-845A-49F1081C0FB0 Q27667482-D680D28D-AE33-4D30-8CD3-141790CF77A1 Q28087213-CB565092-3C60-462D-8C43-B162F48BCCF0 Q28248761-0DE20956-9287-433A-9579-B9D471EACE09 Q28271278-90A01EB4-661B-42F9-9D0C-5E7D098D131D Q28393898-FFA125DF-E027-4BA6-B269-D891365D52EB Q28484079-3BA84EFB-CD8D-4EB3-86F2-444066D7A915 Q28540033-8B0A043E-450B-427A-AEE3-1457E9BA8AD1 Q28551057-9FC9F1AD-ABF4-45C7-8E7B-1E23E93BD8EC Q30009317-1F4B91C4-BFD6-4618-948C-ED7848080AE4 Q30356398-0C6A1305-B3F6-4E5C-9FF6-596C1A39E4BC Q33369693-EE2C5011-3E5A-467C-BC21-98B950B4296C Q33384766-6A41835A-B80F-4C53-B51D-7B2C1C068CE1 Q33442587-E17B965E-6547-4B31-ACDA-F194FCBCC93C Q33597663-011381E6-F6A9-4E7F-90E2-12C5CAF6C1AA Q33608760-A1CEA9EA-7108-48DA-92BB-E686655BDD4E Q33753325-D62B5818-8253-4051-929C-CF6AB4ECD601 Q33770326-66F7AE37-0CC7-4D73-87A8-5A04AF8D741E Q33798573-D7A49746-3A2F-4251-93E9-11BEABBC54DF Q33806036-7AED0C7A-A2D8-4225-8D43-3BDFF861E651 Q33921399-43CF7565-2949-45B2-B4D9-5DB6E5A16889 Q33947776-4507F1C3-9E6F-46D8-8E45-E4E24E46D169 Q33988398-48E8BFE6-933B-43B1-9CF7-48D156E68EDE Q34062313-FC1DAD90-479E-47E3-9DB0-940E2CA5E97E Q34087767-30B9473B-3BDA-4B90-A1AD-BA99E4343543 Q34117463-D163A3AF-2DA6-4B16-90B0-151792FDA5B2 Q34157874-03D90B88-4DC6-4B28-9FFE-2D9FA6D860D1 Q34251497-233614EA-D7E3-449B-943E-CEB3D0BBACA9 Q34272962-CF3F922F-2A0D-4F1C-A46B-9915F2F00CF7 Q34335004-2BA5C5FF-3CC5-4D6C-9F3F-8EFCE4211E7C Q34547402-8E83DAC1-8137-4842-8C07-4B1DE11C4109 Q34632798-C7EB2B64-3B56-46F0-A69D-D537477410BF

P2860

Targeting multiple kinase pathways in leukemic progenitors and stem cells is essential for improved treatment of Ph+ leukemia in mice.

http://www.wikidata.org/entity/Q35119075

description

2006 nî lūn-bûn

@nan

2006 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2006 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

name

Targeting multiple kinase path ...... tment of Ph+ leukemia in mice.

@ast

Targeting multiple kinase path ...... tment of Ph+ leukemia in mice.

@en

type

label

Targeting multiple kinase path ...... tment of Ph+ leukemia in mice.

@ast

Targeting multiple kinase path ...... tment of Ph+ leukemia in mice.

@en

prefLabel

Targeting multiple kinase path ...... tment of Ph+ leukemia in mice.

@ast

Targeting multiple kinase path ...... tment of Ph+ leukemia in mice.

@en

P1433

Q35119075-C82A3075-5014-4362-8264-73ECE7245537

P1476

Q35119075-5B79F7E3-C215-4053-B2CA-E65A97A259E7

P2093

Q35119075-0DD22CC9-E52B-4F09-B2A6-8A50170610C8

Q35119075-8AAF22B2-12F2-472E-A8CC-4A747F0647A1

Q35119075-9563773A-98F6-4CA7-B851-7AAD94CD4AC8

Q35119075-C68DBB85-5DC2-45C1-AAE1-E5F8D4903D31

Q35119075-C6B4FB06-BBA3-43A5-B740-E7C1075D00D0

P2860

Q35119075-12B20B12-B9BA-4975-81DF-B77C931767AB

Q35119075-172FE7A2-2D2D-4841-A84C-2D48020B8A61

Q35119075-1D0F6B4D-6B64-4F9C-9FAD-E204F50B6388

Q35119075-223F7AB2-8CBE-48D3-98F7-50AD2E28D432

Q35119075-43515E89-88D5-4FA6-BD4A-3604C8BD7334

Q35119075-443D6357-97B5-4F80-925A-FD07E22071A0

Q35119075-456EF87B-CFBE-4A3D-BC86-F4914FC78B2A

Q35119075-48A20002-4350-416A-9AF7-6C1970FB3E70

Q35119075-55F9BEDD-0462-4D5C-8FFC-94AACB822932

Q35119075-59525C9E-749E-47D8-B0DC-42A51E2C2848

P304

Q35119075-9DF7EBA7-DB2F-43C2-81AB-868948D920BB

P31

Q35119075-EF50789F-4D36-4635-86AA-D8CF5EB77E15

P356

Q35119075-CFBD9A96-2F33-4881-B042-860448DEBF64

P407

Q35119075-EAABA992-624D-44F2-9623-164A36BB7A18

P433

Q35119075-6952992A-ECFB-4CA7-A793-5134A5018A3B

P478

Q35119075-05C85B7E-30FD-4421-ACA3-EC6116988515

P50

Q35119075-7022FC62-937F-4609-B4A5-01A3BB267416

P577

Q35119075-33499F04-02A1-4A6E-AFD5-756020526441

P5875

Q35119075-CBB82142-C5D7-4F6D-A8F7-4260CE584F4E

P698

Q35119075-A8BE1BFF-3C16-443C-8538-F7BD053E2F50

P921

Q35119075-F0D928B9-29FE-4A21-A16A-B78AAF2D446F

P932

Q35119075-C676CF3D-98FC-4347-835D-0587590837B3

P356

PNAS.0606509103

P1433

Proceedings of the National Academy of Sciences of the United States of America

P1476

Targeting multiple kinase path ...... atment of Ph+ leukemia in mice

@en

P2093

Francis Y Lee

http://www.w3.org/2001/XMLSchema#string

Roberto Weinmann

http://www.w3.org/2001/XMLSchema#string

Sarah Swerdlow

http://www.w3.org/2001/XMLSchema#string

Shaoguang Li

http://www.w3.org/2001/XMLSchema#string

Theodore M Duffy

http://www.w3.org/2001/XMLSchema#string

P2860

Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias

Tyrosine phosphorylation of Grb2 by Bcr/Abl and epidermal growth factor receptor: a novel regulatory mechanism for tyrosine kinase signaling.

Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia

Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML

Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification

Isolation and functional properties of murine hematopoietic stem cells that are replicating in vivo

Overriding imatinib resistance with a novel ABL kinase inhibitor

Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome.

Clinical resistance to the kinase inhibitor STI-571 in chronic myeloid leukemia by mutation of Tyr-253 in the Abl kinase domain P-loop

Inhibition of wild-type and mutant Bcr-Abl by AP23464, a potent ATP-based oncogenic protein kinase inhibitor: implications for CML.

P304

16870-16875

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1073/PNAS.0606509103

http://www.w3.org/2001/XMLSchema#string

P407

P433

45

http://www.w3.org/2001/XMLSchema#string

P478

103

http://www.w3.org/2001/XMLSchema#string

P50

P577

2006-10-31T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

6719703

http://www.w3.org/2001/XMLSchema#string

P698

17077147

http://www.w3.org/2001/XMLSchema#string

P921

P932

1629087

http://www.w3.org/2001/XMLSchema#string